Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

Omar Nadeem / nature - Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04365-yAs presented at the 2026 AACR Annual Meeting, in a phase 2 trial, treatment of patients with high-risk smoldering multiple myeloma with BCMA-targeting CAR T cell therapy cilta…

AI Summary: The CAR-PRISM phase 2 study reports that ciltacabtagene autoleucel, a BCMA-directed CAR T therapy, produced meaningful responses in patients with high‑risk smoldering multiple myeloma, suggesting potential to delay progression to symptomatic disease and defer immediate treatment. Early results show promising efficacy with manageable toxicities, hinting at a shift toward treating disease earlier rather than later.

• CAR-PRISM results: compelling MRD negativity, potential treatment shift (4)
• Experts weigh in: praise, safety concerns, and clinical enthusiasm (4)
• Policy and IO context: regulation, immune engineering, industry implications (3)
• All Other Stories

CAR-PRISM results: compelling MRD negativity, potential treatment shift

Experts weigh in: praise, safety concerns, and clinical enthusiasm

Policy and IO context: regulation, immune engineering, industry implications

All Other Stories